Association of Blood Pressure and Its Evolving Changes With the Survival of Patients With Heart Failure

Journal of Cardiac Failure

Volumn 14, Issue 7, 2008, Pages 561-568

  Grigorian Shamagian, Lilian ^a   Gonzalez JuAnatey, Jose Ramon ^a   Vazquez, Rafael ^b   Cinca, Juan ^c   Bayes Genis, Antoni ^c   Pascual, Domingo ^d   Fernandez Palomeque, Carlos ^e   Bardaji, Alfredo ^f   Almendral, Jesus ^g   Nieto, Vicente ^h   Macaya, Carlos ⁱ   Jimenez, Ricardo Pavon ^b   de Luna, Antoni Bayes ^c  

^a Instituto de Salud Carlos III   (Spain)

^b HOSPITAL UNIVERSITARIO DE VALME   (Spain)

^c Hospital Sant Pau   (Spain)

^d HOSPITAL UNIVERSITARIO VIRGEN DE LA ARRIXACA   (Spain)

^e HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

^f HOSPITAL UNIVERSITARI JOAN XXIII   (Spain)

^g HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^h HOSPITAL UNIVERSITARIO INSULAR DE GRAN CANARIA   (Spain)

ⁱ HOSPITAL CLÍNICO SAN CARLOS   (Spain)

Author keywords

Blood pressure; heart failure; prognosis

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; NITRATE; SPIRONOLACTONE;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; CARDIAC PATIENT; CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; FEMALE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL SOCIETY; MORTALITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; SUDDEN DEATH; SURVIVAL; SYSTOLIC BLOOD PRESSURE;

ADRENERGIC BETA-ANTAGONISTS; AGED; ALDOSTERONE ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; DEATH, SUDDEN, CARDIAC; DIURETICS; FEMALE; FOLLOW-UP STUDIES; HEART ARREST; HEART FAILURE; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; HYPOTENSION; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SPIRONOLACTONE; STROKE VOLUME; SURVIVAL RATE; VENTRICULAR FUNCTION, LEFT;

EID: 49649120943     PISSN: 10719164     EISSN: 15328414     Source Type: Journal    
DOI: 10.1016/j.cardfail.2008.03.006     Document Type: Article

References (19)

1. Georghiade M., Abraham W.T., Albert N.M., Greenberg B.H., O'Connor C.M., She L., et al. Systolic blood pressure at admission, clinical characteristics, and outcomes in patients hospitalized with acute heart failure. JAMA 296 (2006) 2217-2226
2. Yancy C.W., Lopatin M., Stevenson L.W., De Marco T., and Fonarow G.C. ADHERE Scientific Advisory Committee and Investigators. Clinical presentation, management, and in-hospital outcomes of patients admitted with acute decompensated heart failure with preserved systolic function: a report from the Acute Decompensated Heart Failure National Registry (ADHERE) Database. J Am Coll Cardiol 47 (2006) 76-84
3. Komajda M., Lapuerta P., Hermans N., Gonzalez-Juanatey J.R., van Veldhuisen D.J., Erdmann E., et al. Adherence to guidelines is a predictor of outcome in chronic heart failure: the MAHLER survey. Eur Heart J 26 (2005) 1653-1659
4. Rouleau J.L., Roecker E.B., Tendera M., Mohacsi P., Krum H., Katus H.A., et al. Carvedilol Prospective Randomized Cumulative Survival Study Group. Influence of pretreatment systolic blood pressure on the effect of carvedilol in patients with severe chronic heart failure: the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) study. J Am Coll Cardiol 43 (2004) 1423-1429
5. Lee T.T., Chen J., Cohen D.J., and Tsao L. The association between blood pressure and mortality in patients with heart failure. Am Heart J 151 (2006) 76-83
6. Chobanian A.V., Bakris G.L., Black H.R., Cushman W.C., Green L.A., Izzo Jr. J.L., et al. National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The JNC 7 Report. JAMA 289 (2003) 2560-2571
7. ESH-ESC Guidelines Committee. 2003 European Society of Hypertension-European Society of Cardiology. Guidelines for the management of arterial hypertensión. J Hypertension 21 (2003) 1011-1053
8. Cygankiewicz J., Zareba W., Vazquez R., Vallverdu M., Cino J., Cinca J., et al. Relation of heart rate turbulence to severity of heart failure. MUSIC Study. Am J Cardiol 98 (2006) 1635-1640
9. Taylor A.L., Ziesche S., Yancy C., Carson P., D'Agostino Jr. R., Ferdinand K., et al. African-American Heart Failure Trial Investigators. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med 351 (2004) 2049-2057
10. Ghali J.K., Kadakia S., Bhatt A., Cooper R., and Liao Y. Survival of heart failure patients with preserved versus impaired systolic function: the prognostic implication of blood pressure. Am Heart J 123 (1992) 993-997
11. Lee D.S., Austin P.C., Rouleau J.L., Liu P.P., Naimark D., and Tu J.V. Predicting mortality among patients hospitalized for heart failure: derivation and validation of a clinical model. JAMA 290 (2003) 2581-2587
12. Farnett L., Mulrow C.D., Linn W.D., Lucey C.R., and Tuley M.R. The J-curve phenomenon and the treatment of hypertension. Is there a point beyond which pressure reduction is dangerous?. JAMA 265 (1991) 489-495
13. Pepine C.J., Handberg E.M., Cooper-DeHoff R.M., Marks R.G., Kowey P., Messerli F.H., et al. INVEST Investigators A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA 290 (2003) 2805-2816
14. Fletcher A.E., and Bulpitt C.J. How far should blood pressure be lowered?. N Engl J Med 326 (1992) 251-254
15. Pepine C.J., Kowey P.R., Kupfer S., Kolloch R.E., Benetos A., Mancia G., et al. INVEST Investigators. Predictors of adverse outcome among patients with hypertension and coronary artery disease. J Am Coll Cardiol 47 (2006) 547-551
16. Pitt B., Remme W., Zannad F., Neaton J., Martinez F., Roniker B., et al. Eplerenone Post Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left-ventricular dysfunction after myocardial infarction. N Engl J Med 348 (2003) 1309-1321
17. Solomon S.D., Wang D., Finn P., Skali H., Zornoff L., McMurray J.J., et al. Effect of candesartan on cause-specific mortality in heart failure patients: the Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) program. Circulation 110 (2005) 2180-2183
18. Ferrari R., Ceconi C., De Giuli F., Panzali A., and Harris P. Temporal relations of the endocrine response to hypotension with sodium nitroprusside. Cardioscience 3 (1992) 51-59
19. Minaker K.L., Meneilly G.S., Young J.B., Landsberg L., Stoff J.S., Robertson G.L., et al. Blood pressure, pulse, and neurohumoral responses to nitroprusside-induced hypotension in normotensive aging men. J Gerontol 46 (1991) 151-154